University of Cape Town
Browse

H4:IC31 and BCG induced immune responses in a prevention of M. tuberculosis infection efficacy trial

Download (1.82 MB)
dataset
posted on 2020-09-14, 14:23 authored by Virginie RozotVirginie Rozot, Elisa Nemes, Munyaradzi MusvosviMunyaradzi Musvosvi, Asma Toefy, Thomas ScribaThomas Scriba
Immunogenicity responses from the C040-404 clinical trial were measured by whole blood intracellular cytokine staining at baseline and 70 days after vaccination with H4:IC31 (subunit vaccine containing Ag85B and TB10.4), Bacille Calmette-Guerin (BCG, a live attenuated vaccine) or placebo (n=~30 per group) using flow cytometry.

Funding

Aeras

Sanofi Pasteur

Bill and Melinda Gates Foundation

Government of the Netherlands Directorate-General for International Development

the United Kingdom Department of International Development

History

Department/Unit

Department of Pathology

Usage metrics

    South African Tuberculosis Vaccine Initiative (SATVI)

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC